Difference between revisions of "TRERNA1"
(→Lab working on this lncRNA) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 21: | Line 21: | ||
''TRERNA1'' is upregulated in paired clinical breast cancer primary and lymph node metastasis samples <ref name="ref4" /> . | ''TRERNA1'' is upregulated in paired clinical breast cancer primary and lymph node metastasis samples <ref name="ref4" /> . | ||
| − | + | ''TRERNA1'' is overexpression in chronic lymphocytic leukemia (CLL) and high expression is correlated with poor prognostic | |
| + | markers indicating that ''TRERNA1'' expression is part of an aggressive B-cell leukemia phenotype <ref name="ref5" />. | ||
{| class='wikitable' style="text-align:center" | {| class='wikitable' style="text-align:center" | ||
| Line 60: | Line 61: | ||
* Drexel University College of Medicine, Philadelphia, PA, USA.<ref name="ref4" /> | * Drexel University College of Medicine, Philadelphia, PA, USA.<ref name="ref4" /> | ||
* Max Planck Institute for Molecular Genetics, Berlin, Germany.<ref name="ref4" /> | * Max Planck Institute for Molecular Genetics, Berlin, Germany.<ref name="ref4" /> | ||
| − | * Division of Endocrine and Oncologic Surgery, Department of Surgery and Rena Rowan Breast Center, Perelman School of Medicine, Abramson Cancer | + | * Division of Endocrine and Oncologic Surgery, Department of Surgery and Rena Rowan Breast Center, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> |
| − | Center, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> | ||
* Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> | * Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> | ||
* Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> | * Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.<ref name="ref4" /> | ||
* Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA.<ref name="ref5" /> | * Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA.<ref name="ref5" /> | ||
* The Chronic Lymphocytic Leukemia (CLL) Research Consortium, La Jolla, CA, USA.<ref name="ref5" /> | * The Chronic Lymphocytic Leukemia (CLL) Research Consortium, La Jolla, CA, USA.<ref name="ref5" /> | ||
| + | |||
==References== | ==References== | ||
<references> | <references> | ||
Latest revision as of 08:15, 21 November 2018
TRERNA1 translation regulatory long non-coding RNA 1 gene function as an Enhancer of SNAI1.
Contents
Annotated Information
Name
TRERNA1: Translation regulatory long non-coding RNA 1 (HGNC nomenclarure), LINC00651
Synonyms: ncRNA-a7, treRNA
Characteristics
TRERNA1 is two exon transcript of 615 bp (GenBank) long non coding RNA that is located on human chromosome 20q13.13 [1][2]. In 150 kb neighbor regions to TRERNA1 there are five protein-coding genes: SNAI1, UBE2V1, TMEM189, CEBPB, and RNF114 [1]. TRERNA1 transcript is spliced and polyadenylated [2].
Functions
TRERNA1 as a regulator of SNAI1 expression. The relative position of the adjacent gene to the TRERNA1 and the effects on mRNA levels for the surrounding genes after knockdown or enforced expression of TRERNA1 in MKN-28 and AGS cells [1].
TRERNA1 fraction in the nucleus acts as an enhancer-like function to suppress CDH1 expression by enhancing transcription of the SNAI1 gene and epigenetically silencing the expression of CDH1 by binding to PRC2 [1].
TRERNA1 promoted cell migration and invasion in gastric cancer (GC) [3]. TRERNA1 epigenetically silenced CDH1 expression by physical association with EZH2 in GC cells [1].
Expression
TRERNA1 is upregulated in gastric carcinogenesis [3].
TRERNA1 is upregulated in paired clinical breast cancer primary and lymph node metastasis samples [2] .
TRERNA1 is overexpression in chronic lymphocytic leukemia (CLL) and high expression is correlated with poor prognostic markers indicating that TRERNA1 expression is part of an aggressive B-cell leukemia phenotype [4].
| Experiment | Forward primer | Reverse primer |
|---|---|---|
| Quantitative PCR | 5'-CCGTTGGCTCCACAAACCT- 3' | 5'-CAGTGACAGTAGCAGGCATCCT- 3'[5] |
| PCR | 5′‐AATGAAAACACCAGGCCGGG‐3′ | 5′‐TCTCACTCTCTCAA ATCGGC‐3′[2] |
| In Vitro Translation | GGC AGA GAC GGA GAA GAT GA | GCC TTA GAC TGT GAA ATT TTA TTG A [5] |
Regulation
Transcription factor, activating enhancer‑binding protein 4 (TFAP4) regulates TRERNA1 by binding to the E‑box motifs in the TRERNA1 promoter [3]
Disease
Lab working on this lncRNA
- Department of Medical Genetics and Developmental Biology, Medical School of Southeast University, The Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Southeast University, Nanjing 210009, China.[1]
- School of Life Science, Bengbu Medical College, Bengbu 233030, China.[1]
- Third Affiliated Hospital of Harbin Medical University (Harbin Medical University Cancer Hospital), Harbin 150040, China.[1]
- Department of Pathophysiology, Medical School of Southeast University, Nanjing 210009, China.[1]
- The Wistar Institute, Philadelphia, PA, USA.[2]
- University of Washington Medical Center, Seattle, WA, USA.[2]
- Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.[2]
- Drexel University College of Medicine, Philadelphia, PA, USA.[2]
- Max Planck Institute for Molecular Genetics, Berlin, Germany.[2]
- Division of Endocrine and Oncologic Surgery, Department of Surgery and Rena Rowan Breast Center, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.[2]
- Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA, USA.[2]
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.[2]
- Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA.[4]
- The Chronic Lymphocytic Leukemia (CLL) Research Consortium, La Jolla, CA, USA.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Wu H, Hu Y, Liu X, Song W, Gong P, Zhang K et al. LncRNA TRERNA1 function as an enhancer of SNAI1 promotes gastric cancer metastasis by regulating epithelial-mesenchymal transition[J]. Molecular Therapy-Nucleic Acids. 2017, 8:291-299.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 Gumireddy K, Li A, Yan J, Setoyama T, Johannes GJ, Ørom UA et al. Identification of a long non‐coding RNA‐associated RNP complex regulating metastasis at the translational step[J]. The EMBO journal. 2013, 32(20):2672-2684.
- ↑ 3.0 3.1 3.2 3.3 Wu H, Liu X, Gong P, Song W, Zhou M, Li Y et al. Elevated TFAP4 regulates lncRNA TRERNA1 to promote cell migration and invasion in gastric cancer[J]. Oncology reports. 2018.
- ↑ 4.0 4.1 4.2 4.3 Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A et al. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia[J]. Oncotarget. 2017, 8(16):25942.
- ↑ 5.0 5.1 Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G et al. Long noncoding RNAs with enhancer-like function in human cells[J]. Cell. 2010, 143(1): 46-58.
Sequence
>gi|389565506|ref|NR_051976.1| Homo sapiens translation regulatory long non-coding RNA 1 (TRERNA1), long non-coding RNA
000001 CCGTTCCTGC CTCCCACAGA CACCTATTAA GTGCCTCCAG TTTTAGGAAC TGGGTATAGA TATGGCTGGG AACAAAATGG 000080
000081 AAGAAAACAA AAACAAAAAT CCCTGCCCTC ATGGTGCTGA CTCTCCTGTG GCAGAGACGG AGAAGATGAA CAGGGATTTT 000160
000161 ATACCAGGCG TCAGAAGGGA ACCAGTGCTA AAGAAAATGA AAACACCAGG CCGGGAGAGG CAGCTGGCAT GCGGGCCGTG 000240
000241 GTGGTTTTAC GTGGCCGATT TGAGAGAGTG AGACCCCTGG GGTCTTGGAG CCAGGCCTGG GAAAAGCTAC TTCACGTCAG 000320
000321 GCCAGGGGCT GTAGCCCTGG CAACCTCCAC TCCGCCTGGA AATCCTCCAC CTCGGGGCCT CTCTTTGCCC AGACCTGGCC 000400
000401 CAGGAGGAGC ACATGGGAGC CGGGACCTTC CCAACAATCC TTGCCGTTGG CTCCACAAAC CTCAGCCAGT CCTGCAACCT 000480
000481 GGGATGCCTT TTCCACCAGG ATGCCTGCTA CTGTCACTGT TGTCATTAGA TAATTAATGA ACTATAATTA GAAATCATAT 000560
000561 CAATAAAATT TCACAGTCTA AGGCTGTTGA AATAGGAAAA AAAAAAAAAA AAAAA
000081 AAGAAAACAA AAACAAAAAT CCCTGCCCTC ATGGTGCTGA CTCTCCTGTG GCAGAGACGG AGAAGATGAA CAGGGATTTT 000160
000161 ATACCAGGCG TCAGAAGGGA ACCAGTGCTA AAGAAAATGA AAACACCAGG CCGGGAGAGG CAGCTGGCAT GCGGGCCGTG 000240
000241 GTGGTTTTAC GTGGCCGATT TGAGAGAGTG AGACCCCTGG GGTCTTGGAG CCAGGCCTGG GAAAAGCTAC TTCACGTCAG 000320
000321 GCCAGGGGCT GTAGCCCTGG CAACCTCCAC TCCGCCTGGA AATCCTCCAC CTCGGGGCCT CTCTTTGCCC AGACCTGGCC 000400
000401 CAGGAGGAGC ACATGGGAGC CGGGACCTTC CCAACAATCC TTGCCGTTGG CTCCACAAAC CTCAGCCAGT CCTGCAACCT 000480
000481 GGGATGCCTT TTCCACCAGG ATGCCTGCTA CTGTCACTGT TGTCATTAGA TAATTAATGA ACTATAATTA GAAATCATAT 000560
000561 CAATAAAATT TCACAGTCTA AGGCTGTTGA AATAGGAAAA AAAAAAAAAA AAAAA
